Global PrEP Tracker
This sortable database includes quarterly updates on national programs delivering oral PrEP, country guidelines and targets, drug registration status and more.
Countries are at varying stages of introducing daily oral tenofovir-based PrEP, which is recommended by WHO as a prevention option for people at substantial risk of HIV. Some countries have national programs; others have smaller-scale programs; others aren’t offering PrEP at all.
In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not. Want to take the next step in expanding access to PrEP? Check out PrEP Planning A-Z.
This step-by-step framework for scaling up PrEP outlines what's involved for introducing oral PrEP and provides links to tools and resources.
This sortable database includes quarterly updates on national programs delivering oral PrEP, country guidelines and targets, drug registration status and more.
As oral PrEP rolls out globally, implementers are facing and overcoming real-world obstacles. Lessons from the Field brings you these stories. Come here to learn from others, sharpen insights and find useful resources.
An analysis of global PrEP uptake, based on quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and data from manufacturers and government agencies.
July 10, 2019
In Australia, more than 40 percent of gay men considered to be most at risk of infection are on PrEP. “Provided we don’t take our foot off the pedal, we stand a chance of eliminating HIV by 2030” in Australia, said Andrew Grulich, professor of epidemiology at the University of New South Wales.
June 11, 2019
The US Preventive Services Task Force issued a recommendation today calling on health care providers to offer pre-exposure prophylaxis, or PrEP, to men and women at high risk of acquiring HIV. The Affordable Care Act requires private insurers to cover preventive services recommended by the USPSTF with an “A” or “B” rating.
May 16, 2019
The chief executive of Gilead Sciences, the nation’s leading manufacturer of HIV drugs, insisted before a House committee Thursday that a government patent on Truvada, a key drug that prevents the infection, is invalid.